Vaccination of Advanced-Stage Lung Cancer Patients

Lung Neoplasms Clinical Trial

Official title:

"Vaccination of Advanced-Stage Lung Cancer Patients" A Phase I/II Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDETM ISA 51 VG ST Adjuvant

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02264236
• Other study ID #: 203199
• Secondary ID: 203199
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: October 2015
• Est. completion date: June 2021

Study information

• Verified date: June 2021
• Source: University of Arkansas
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching purpose of this study is to evaluate the clinical efficacy of an investigational agent, P10s-PADRE, a peptide mimotope-based vaccine, in combination with standard-of-care (SoC) treatment in subjects with advanced-stage (i.e., metastatic) Lung Cancer. Vaccine will consist of P10s-PADRE admixed with an adjuvant, MONTANIDETM ISA 51 VG. Up to one hundred fifty (150) subjects with advanced-stage Lung Cancer of any histologic type will be enrolled for this vaccine trial.

This single-arm, multi-site trial is designed to evaluate the therapeutic benefits of the vaccine in subjects with advanced-stage lung cancer. The primary objectives of the study are: (1) to monitor the safety and tolerability of the vaccine when it is administered in combination with SoC therapy; and (2) to determine whether immunization with vaccine can successfully elicit a robust immune response in subjects with advanced-stage lung cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Advanced-stage (i.e., metastatic) Lung Cancer of any histologic type

2. (Computed Tomography) CT scans were completed within 4 weeks prior to registration

3. Age 18 years and older

4. ECOG Performance Status 0 to 2

5. White blood cell (WBC) count = 3,000/mm3 within 3 weeks prior to registration

6. Platelet count = 100,000/mm3 within 3 weeks prior to registration

7. Serum glutamic-pyruvic transaminase (SGPT) or alanine aminotransferase test (ALT) = 2 x institutional upper limit (IUL) of normal obtained within 3 weeks prior to registration

8. Serum glutamic-oxaloacetic transaminase (SGOT) or aspartate aminotransferase test (AST) = 2 x institutional upper limit (IUL) of normal obtained within 3 weeks prior to registration

9. Serum creatinine = 1.8 mg/dL obtained within 3 weeks prior to registration

10. Radiation is allowed

Exclusion Criteria:

1. Active infection requiring treatment with antibiotics

2. Any other significant medical or psychiatric conditions which, in the opinion of the enrolling investigator, may interfere with consent or compliance of the treatment regimen

3. Existing diagnosis or evidence of organic brain syndrome that might preclude participation in the full protocol

4. Existing diagnosis or history of significant impairment of basal cognitive function that might preclude participation in the full protocol

5. Existing diagnosis or history of leptomeningeal disease, spinal cord compression or brain metastases unless: (a) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment, AND (b) subject has no residual neurological dysfunction and has been off corticosteroids for at least 14 days prior to registration

6. Other current malignancy(s): Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration. Subject has other malignancies have been continuously disease free for = 5 years prior to the time of registration. Subjects with other malignancies are eligible if they have been continuously disease free for = 5 years prior to the time of registration.

7. Active autoimmune disorders or conditions of immunosuppression; Existing autoimmune disorders or conditions of immunosuppression that have been in remission for less than 6 months.

8. Treatment with corticosteroids, including oral steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or ointments or any steroid-containing inhalers. Subjects who have been on systemic steroids will require a 6-week washout period. Subjects who discontinue the use of these classes of medication for at least 6 weeks prior to registration are eligible if, in the judgment of the treating physician, the subject is not likely to require these classes of drugs during the treatment period. Replacement doses of steroids for subjects with adrenal insufficiency are allowed.

Related Conditions & MeSH terms

• Lung Neoplasms

Intervention

Biological:
• P10s-PADRE vaccine
P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG "Chemotherapy" Subcutaneous injection at weeks 2, 3, 5, and 6. "3-Week Interval Immunotherapy" Subcutaneous injection at weeks 2, 3, and 4. "2-Week Interval Immunotherapy" Subcutaneous injection at weeks 3, 4, and 5.

Locations

Country	Name	City	State
United States	University of Arkansas for Medical Sciences	Little Rock	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with vaccine related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.	The National Cancer Institute (NCI) of the National Institutes of Health (NIH) has published standardized definitions for adverse events (AEs), known as the Common Terminology Criteria for Adverse Events (CTCAE, also called "common toxicity criteria"), to describe the severity of organ toxicity for patients receiving cancer therapy. The tables describing AEs graded in the CTCAE (version 4.0) provides a references for adverse events reporting. From grade 1 AEs being minor/low grade adverse events to grade 5 AEs being serious adverse events usually resulting in death.	64 weeks +/- 2 weeks per subject
Primary	Number of participants with vaccine induced immune related response.		64 weeks +/- 2 weeks per subject